Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: Evidence for early control of pertussis

Infection and Immunity

Volumn 70, Issue 7, 2002, Pages 3521-3528

  Roduit, Caroline ^a   Bozzotti, Paola ^a   Mielcarek, Nathalie ^a   Lambert, Paul Henri ^a   Del Giudice, Giuseppe ^a   Locht, Camille ^a   Siegrist, Claire Anne ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CLEARANCE; CONTROLLED STUDY; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFANT; INFECTION CONTROL; INFECTION PREVENTION; MOUSE; NEWBORN; NEWBORN CARE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; TIME SERIES ANALYSIS; VACCINATION;

ADHESINS, BACTERIAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DISEASE MODELS, ANIMAL; HEMAGGLUTININS; MICE; MICE, INBRED BALB C; PERTUSSIS TOXIN; VACCINATION; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 0036087959     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.7.3521-3528.2002     Document Type: Article

References (40)

1. Review: Protective efficacy of hepatitis B vaccines in neonates
2. Immunologic response to early and routine DTP immunization in infants
3. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: Predominance of a Th2-biased pattern which persists after adult boosting
4. Control of hepatitis B: Evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers
5. The 1996 pertussis epidemic in New Zealand: Descriptive epidemiology
6. Intranasal murine model of Bordetella pertussis infection. II. Sequence variation and protection induced by a tricomponent acellular vaccine
7. Epidemiological, clinical, and laboratory aspects of pertussis in adults
8. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses
9. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin)
10. Is pertussis a frequent cause of cough in adolescents and adults? Should routine pertussis immunization be recommended?
11. Hospital admissions for pertussis in Spain, 1995-1998
12. Simple solid phase assays of avidity
13. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
14. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines
15. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine
16. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: Report of the Immunization Monitoring Program-Active (IMPACT)
17. Pertussis in the young infant
18. Pertussis: A worldwide problem
19. Neonatal immunization: Response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine
20. Efficacy of a two-component acellular pertussis vaccine in infants
21. The measurement of relative antibody affinity by ELISA using thiocyanate elution
22. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells
23. The vaccination of the newborn infant against pertussis
24. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA)
25. Surface-associated filamentous hemagglutinin induces autoagglutination of Bordetella pertussis
26. Immunity to Bordetella pertussis
27. A respiratory challenge model for infection with Bordetella pertussis: Application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity
28. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis
29. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
30. Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth
31. Pertussis in South Australia 1893 to 1996
32. Efficacy of acellular pertussis vaccine in early childhood after household exposure
33. Neonatal and early life vaccinology
34. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal
35. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine
36. Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection
37. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
38. Pertussis in young infants
39. Pertussis deaths: Report of 23 cases in the United States, 1992 and 1993
40. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines